Abstracts tagged "autoantibodies"

Abstract Number: 2296 • 2018 ACR/ARHP Annual Meeting
Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
Sang Wan Chung¹, Su-Jin Yoo², Seong-Wook Kang³, In-Seol Yoo³, Seung-Cheol Shim³, Mihye Kwon⁴, Chung-Il Joung⁴, Jinhyun Kim⁵, Seung-Jae Hong¹ and Yeon-Ah Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ²Departmen of Internal medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ³Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁴Department of Internal Medicine, Konyang University hospital, Daejeon, Korea, Republic of (South), ⁵Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁶Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South)
Novel Classification Of Idiopathic Inflammatory Myopathies Based On Distinctive Features And Autoantibodies: Analysis Of 67 Korean PatientsBackground/Purpose: Since Bohan and Peter first described their diagnostic…
Abstract Number: 106 • 2018 ACR/ARHP Annual Meeting
Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Richard Moore¹ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: We recently described the phenomenon in systemic lupus erythematosus (SLE) in which mitochondria are extruded into the extracellular space during formation of neutrophil extracellular…
Abstract Number: 1089 • 2018 ACR/ARHP Annual Meeting
Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms
Robert M. Clancy¹, Carl Langefeld², Hannah C. Ainsworth³, H. Michael Belmont¹, Martin Blaser⁴, Peter M. Izmirly⁵, Corey Lacher¹, Miranda C Marion⁶, Mala Masson¹, Gregg Silverman⁷ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Director of the NYU Human Microbiome Program, NYU School of Medicine, New York, NY, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-Ro60 autoantibodies are present in asymptomatic individuals years before onset of disease. We hypothesize that differences in autoreactivity-inducing commensal abundances may drive progression to…
Abstract Number: 1699 • 2018 ACR/ARHP Annual Meeting
Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus
May Choi¹, Eric Campbell², Ann E. Clarke¹, Michelle Jung², Claire Barber³, Yvan St.Pierre⁴ and Marvin J. Fritzler¹, ¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: M-phase phosphoprotein (MPP-1), also termed kinesin interacting protein (KIF20B), is a 210 kDa protein that is highly expressed during cell division. Autoantibodies to MPP-1…
Abstract Number: 2421 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Isabel Añón Oñate¹, Irene Notario¹, Miguel Ángel Ferrer¹, Lorena Pérez¹, María Ramírez¹ and Rafael Cáliz², ¹Rheumatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain
Background/Purpose: To evaluate the efficacy of the treatment on the pregnancy outcomes of women with Rheumatic Diseases and Thrombophilia from a Spanish cohort. Their pregnancies…
Abstract Number: 137 • 2018 ACR/ARHP Annual Meeting
Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Ken Tsumiyama and Shunichi Shiozawa, Institute for Rheumatic Diseases, Nagahama, Japan
Background/Purpose: We have shown that repeated immunization with antigen induces systemic lupus erythematosus (SLE) in the mice otherwise not prone to spontaneous autoimmune diseases. We…
Abstract Number: 1120 • 2018 ACR/ARHP Annual Meeting
Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort
Pravitt Gourh¹, Elaine F. Remmers², Theresa Alexander³, Steven Boyden⁴, Nadia D. Morgan⁵, Ami A. Shah⁶, Maureen D. Mayes⁷, Ayo Doumatey², Amy Bentley², Daniel Shriner⁸, Robyn T. Domsic⁹, Thomas A. Medsger Jr.¹⁰, Virginia D. Steen¹¹, Paula S. Ramos¹², Rick Silver¹³, Benjamin D. Korman¹⁴, John Varga¹⁵, Elena Schiopu¹⁶, Dinesh Khanna¹⁷, Vivien Hsu¹⁸, Jessica K. Gordon¹⁹, Lesley Ann Saketkoo²⁰, Heather Gladue²¹, Brynn Kron²², Lindsey A. Criswell²², Chris T. Derk²³, S. Louis Bridges Jr.²⁴, Victoria Shanmugam²⁵, Kathleen D. Kolstad²⁶, Lorinda Chung²⁷, Reem Jan²⁸, Elana J. Bernstein²⁹, Avram Goldberg³⁰, Marcin Trojanowski³¹, Suzanne Kafaja³², Kathleen Maksimowicz-McKinnon³³, Settara C Chandrasekharappa², Adebowale Adeyemo², Charles Rotimi², Fredrick M. Wigley³⁴, Francesco Boin³⁵ and Daniel L. Kastner³⁶, ¹NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, ⁹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹²Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ¹⁵Northwestern University, Chicago, IL, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁹Rheumatology, Hospital for Special Surgery, New York, NY, ²⁰Tulane, New Orleans, LA, ²¹Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²²University of California San Francisco, San Francisco, CA, ²³Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁴Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ²⁵Rheumatology, The George Washington University, Washington, DC, ²⁶Rheumatology, Stanford University Medical Center, Stanford, CA, ²⁷Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Medicine, Rheumatology, University of Chicago, Chicago, IL, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰NYU Langone Medical Center, New York, NY, ³¹Boston University, Boston, MA, ³²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³³Rheumatology, Henry Ford Hospital, Detroit, MI, ³⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁵Rheumatology, University California, San Francisco, San Francisco, CA, ³⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-fibrillarin (nucleolar, AFA) and anti-topoisomerase I (ATA) autoantibodies are specific to systemic sclerosis (SSc) and are common in African Americans (AA). These autoantibodies define…
Abstract Number: 1721 • 2018 ACR/ARHP Annual Meeting
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
Veronika K. Jaeger¹, Elise Siegert², Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci-Cerinic⁶, Oliver Distler⁷, Franco Cozzi⁸, Yannick Allanore⁹, Mangtao Li¹⁰, Mohammed Tikly¹¹ and Ulrich A. Walker¹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Second University of Naples, Naples, Italy, ⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁹Immunogenetics, Cochin Institute, Paris, France, ¹⁰Peking Union Medical College Hospital, Beijing, China, ¹¹Division of Rheumatology, Department of Internal Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Genetic and environmental factors play a significant role in SSc. African Americans are known for a higher SSc incidence, an earlier age of onset,…
Abstract Number: 2506 • 2018 ACR/ARHP Annual Meeting
The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only
Evo Alemao¹, Yogesh Saini², Ying Bao¹, Aarti Rao², Christine K Iannaccone³, Michael E Weinblatt³ and Nancy A. Shadick³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered a poor prognostic factor in RA and is a common extra-articular manifestation of RA. We estimated prevalence of…
Abstract Number: 288 • 2018 ACR/ARHP Annual Meeting
Burden of Illness of Treating Patients with Pemphigus vulgaris
Jennie H. Best, Margaret Michalska and Ibrahim Abbass, Genentech, Inc., South San Francisco, CA
Background/Purpose: Pemphigus vulgaris (PV) is a rare autoimmune disorder that affects the skin and mucous membranes. Many patients with PV suffer from serious infections, and…
Abstract Number: 1306 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)
Giorgos Loizidis¹, Nikhil Jiwrajka², Colin Ligon³, Mary Porteous² and Michael D. George⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Internal Medicine, Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) has recently been defined to describe patients with interstitial lung disease (ILD) with certain clinical, serologic, and/or morphologic…
Abstract Number: 1737 • 2018 ACR/ARHP Annual Meeting
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
Paul J. Utz¹ and Burcu Ayoglu², ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Medicine, Stanford University, STANFORD, CA
Background/Purpose: In a randomized, open-label, phase II clinical trial (SCOT, Scleroderma: Cyclophosphamide or Transplantation)1, subjects were randomly assigned to treatment with myeloablative CD34+ selected autologous…
Abstract Number: 2793 • 2018 ACR/ARHP Annual Meeting
Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis
Natalia Sherina¹, Natalie Sippl¹, Lena Israelsson¹, Erwan Le Maitre², Nastya Kharlamova¹, Monika Hansson³, Kaja Eriksson⁴, Tulay Yucel-Lindberg⁴, Khaled Amara¹ and Karin Lundberg¹, ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Solna,, Karolinska Institutet, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPA) is a hallmark of rheumatoid arthritis (RA). ACPAs specifically recognize citrullinated epitopes, a result of a post-translational…
Abstract Number: 375 • 2018 ACR/ARHP Annual Meeting
Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
Johannes Knitza, Hannah Schenker, Georg Schett and Jörg Distler, Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Antisynthetase Syndrome is a rare and severe autoimmune inflammatory disease that is associated with autoimmunity against aminoacyl-tRNA synthetase and clinical signs of arthritis, myositis…
Abstract Number: 1307 • 2018 ACR/ARHP Annual Meeting
Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
Adelle S Jee^1,2, Jane F Bleasel^3,4, Stephen Adelstein^4,5,6, Lauren Troy^1,4, Helen Jo^1,4, Edmund Lau^1,4, Susanne Webster¹ and Tamera J Corte^7,8, ¹Respiratory and Sleep Department, Royal Prince Alfred Hospital, Sydney, Australia, ²Medicine Central clinical school, University of Sydney, Sydney, Australia, ³Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, ⁴Faculty of Medicine, University of Sydney, Sydney, Australia, ⁵Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, Australia, ⁶Immunopathology Laboratory, South-west Sydney Pathology Service, Sydney, Australia, ⁷Royal Prince Alfred Hospital, Sydney, Australia, ⁸University of Sydney, Sydney, Australia
Background/Purpose: The detection of autoantibodies plays a vital role in the diagnosis of occult connective tissue disease (CTD) in patients with interstitial lung disease (ILD),…

« Previous Page
1
…
3
4
5
6
7
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].